Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2016 - 2025)

Viking Therapeutics' Change in Acquisitions & Divestments history spans 11 years, with the latest figure at $116.1 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 19.12% year-over-year to $116.1 million; the TTM value through Dec 2025 reached $759.4 million, up 35.61%, while the annual FY2025 figure was $759.4 million, 35.61% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $116.1 million at Viking Therapeutics, down from $181.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $295.9 million in Q1 2025 and bottomed at $32.3 million in Q1 2022.
  • The 5-year median for Change in Acquisitions & Divestments is $65.0 million (2021), against an average of $100.0 million.
  • The largest annual shift saw Change in Acquisitions & Divestments plummeted 61.85% in 2021 before it surged 163.05% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $63.0 million in 2021, then dropped by 17.65% to $51.9 million in 2022, then surged by 156.94% to $133.3 million in 2023, then grew by 7.71% to $143.5 million in 2024, then fell by 19.12% to $116.1 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Change in Acquisitions & Divestments are $116.1 million (Q4 2025), $181.5 million (Q3 2025), and $166.0 million (Q2 2025).